Quest Diagnostics director awarded 1,142 RSUs

Quest Diagnostics director Denise M. Morrison received an award of 1,142 shares of Common Stock on May 20, 2026 as a grant of restricted stock units.

Accepted by SEC EDGAR 05/21/2026 - 04:53 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Quest Diagnostics director Denise M. Morrison received an award of 1,142 shares of Common Stock on May 20, 2026 as a grant of restricted stock units. The award was made at no cash cost per share and increased her direct holdings to 11,929 shares.

The total includes shares acquired through dividend reinvestment since her last Form 4 under the Amended and Restated Deferred Compensation Plan for Directors.

Insider Trade Summary

Grant/Award: 1,142 shares

Grant/Award 1 txn

Insider MORRISON DENISE M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,142	$0.00	$0.00

Holdings After Transaction: Common Stock — 11,929 shares (Direct)

Footnotes (2)

1. F1. Represents an award of restricted stock units.
2. F2. The amount includes shares acquired via dividend reinvestment since the date of reporting person's last filing on Form 4 pursuant to the Amended and Restated Deferred Compensation Plan for Directors.

Key Figures

RSU grant size: 1,142 shares Grant price: $0.0000 per share Shares after transaction: 11,929 shares +1 more

4 metrics

RSU grant size 1,142 shares Restricted stock unit award on May 20, 2026

Grant price $0.0000 per share Non-cash equity grant to director

Shares after transaction 11,929 shares Director’s direct holdings following RSU grant

Net buy/sell direction Neutral (no open-market buys or sells) Transaction summary for this Form 4

Key Terms

restricted stock units, dividend reinvestment, Amended and Restated Deferred Compensation Plan for Directors, Form 4

4 terms

restricted stock units financial

"Represents an award of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

dividend reinvestment financial

"includes shares acquired via dividend reinvestment since the date of reporting person's last filing"

Dividend reinvestment is when the money earned from a company's profit sharing, called dividends, is automatically used to buy more shares of that company instead of being received as cash. This process helps investors grow their holdings over time without extra effort, much like using earned interest to buy more of a savings account. It encourages long-term investment growth by continuously increasing the amount of shares owned.

Amended and Restated Deferred Compensation Plan for Directors financial

"pursuant to the Amended and Restated Deferred Compensation Plan for Directors."

Form 4 regulatory

"since the date of reporting person's last filing on Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Quest Diagnostics (DGX) director Denise Morrison report in this Form 4?

Denise Morrison reported receiving 1,142 shares of Quest Diagnostics Common Stock as a grant of restricted stock units. This non-cash award increased her direct holdings to 11,929 shares, according to the Form 4 transaction and related footnotes.

How many Quest Diagnostics (DGX) shares does Denise Morrison hold after this grant?

After the award, Denise Morrison directly holds 11,929 shares of Quest Diagnostics Common Stock. This figure includes the 1,142-share restricted stock unit grant and shares accumulated via dividend reinvestment under the directors’ deferred compensation plan since her prior Form 4.

Was cash paid for the 1,142 Quest Diagnostics (DGX) shares granted to Denise Morrison?

No cash was paid for the 1,142-share award to Denise Morrison. The Form 4 lists a transaction price per share of 0.0000, indicating a non-cash grant of restricted stock units rather than an open-market purchase of Quest Diagnostics shares.

What type of equity award did Quest Diagnostics (DGX) grant to Denise Morrison?

The filing describes the award as restricted stock units tied to Quest Diagnostics Common Stock. A footnote states it “represents an award of restricted stock units,” clarifying that the transaction is a compensation-related equity grant, not a market purchase or sale of existing shares.

How were dividend reinvestments reflected in Denise Morrison’s Quest Diagnostics (DGX) holdings?

Her reported 11,929-share total includes shares acquired through dividend reinvestment. A footnote explains these additions occurred since her last Form 4 under the Amended and Restated Deferred Compensation Plan for Directors, consolidating those reinvested amounts into the current holding figure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MORRISON DENISE M

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NEW JERSEY 07094

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	05/20/2026		A		1,142	A	$0	11,929(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units.

2. The amount includes shares acquired via dividend reinvestment since the date of reporting person's last filing on Form 4 pursuant to the Amended and Restated Deferred Compensation Plan for Directors.

Remarks:

	Sean D. Mersten, Attorney in Fact for Denise M. Morrison	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)